Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Molecularly Driven, Immune-Based, Maintenance Niraparib and Dostarlimab in Advanced Stage Cholangiocarcinoma

NCT04895046 is registered in ClinicalTrials.gov with Walid Shaib, MD as lead sponsor.

NCT NCT04895046
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04895046 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Molecularly Driven, Immune-Based, Maintenance Niraparib and Dostarlimab in Advanced Stage Cholangiocarcinoma
Lead sponsor
Walid Shaib, MD
Phase
Phase 2
Overall status
Withdrawn
Start date
October 11, 2021
Completion date
September 30, 2023
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cholangiocarcinoma, hrd, metastatic cancer